SAN DIEGO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from two 24-week Phase 3 clinical studies examining the investigational ...
In order to evaluate whether the action of M4 was additive or synergistic in H460 and H460/TaxR cells, we analyzed the combination effects using the combination index (CI) method. 26 The Fa-CI plot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback